Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)

References

• Hartmann, M. and Zimmer, C.H. (1972) "Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393, and 3943", Biochimica et Biophysiologica Acta, 287, 386–389.
   Google Scholar
• Ozegowski, W. and Krebs, D. (1971) "7-(1-Mehy1-5-bis4/3-chlor- dthyl)-amino-benzimidazoly1-(2)]-buttersdurehydrochlorid,emnneues Zytostatikum aus der Reihe der Benzimidazol-Loste", Zentralblatt fur Pharmakologie, 110, 1013 — 1019.
   Google Scholar
• Staib, P., Schinköhe, T., Dimski, T., Lathan, B., Horn, P.A., Voliotis, D., Tesch, H. and Diehl, V. (1999) "In-vitro modulation of Ara-CTP accumulation in fresh AML cells by bendamustin in comparison with fludarabine, 2-CDA and gemcitabine", Blood, 94, 63a (abstr).
   Google Scholar
• Kath, R., Blumenstengel, K., Fricke, H.J. and Höffken, K. (2001) "Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia", Journal of Cancer Research and Clinical Oncology, 127, 48 — 54.
   Google Scholar
• Heider, A. and Niederle, N. (2001) "Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas", Anti-Cancer Drugs, 12, 725–729.
   Google Scholar
• Bremer, K. (2002) "High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas", Journal of Cancer Research and Clinical Oncology, 128, 603–609.
   Google Scholar
• Weidmann, E., Kim, S.-K., Rost, A., Schuppert, H., Seipelt, G., Hoelzer, D. and Mitrou, P.S. (2002) "Bendamustine is effective in relapsed and refractory aggressive non-Hodgkin's lymphoma", Annals of Oncology, 13, 1285 — 1289.
   Google Scholar
• Piinisch, W. and Niederwieser, D. (2002) "Bendamustine in the treatment of multiple myeloma: results and future perspectives", Seminars in Oncology, 29 (Suppl. 13), 23–26.
   Google Scholar
• Weide, R., Heymanns, J., Gores, A. and Köppler, H. (2002) "Bendamustine, mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas", Leukemia and Lymphoma, 43, 327–331.
   Google Scholar
• Kath, R., Blumenstengel, K., Fricke, H.J., Peters, H.D. and Höffken, K. (2001) "Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma", Deutsche Medizinische Wochenschrift, 126, 198–202.
   Google Scholar
• Herold, M., Schulze, A., Mantovani, L., Franke, A., Freund, M., Ismer, B., et al. (1999) "BOP versus COP in advanced low grade non-Hodgkin's lymphomas—results of a randomized multicenter study", Blood, 94, 262b.
   Google Scholar
• Herold, M., Anger, G., Höche, D. and Kästner, R. (1987) "Vorläufige Ergebnisse einer zyklisch-alternierenden Chemothera-pie (CVPP/DBVCy) bei fortgeschrittenem Morbus Hodgkin", Medizinische Klinik, 10, 345–349.
   Google Scholar
• Kahl, C., Herold, M., Hakes, H.G. and Franke, A. (1997) "Bendamustine, methotrexate, mitoxantrone and prednisolone (BMMP) for the treatment of relapsed or refractory high-grade non-Hodgkin's lymphoma", Onkologie, 20, 406–408.
   Google Scholar
• Rummel, M.J., Mitrou, P.S. and Hoelzer, D. (2002) "Bendamustine in the treatment of Non-Hodgkin's lymphoma: results and future perspectives", Seminars in Oncology, 29, 27— 32.
   Google Scholar
• Klasa, R.J., Meyer, R.M., Shustik, C., Sawka, C.A., Smith, A., Guevin, R., et al. (2002) "Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients previously treated with an alkalating agent or alkylator-containing regimen", Journal of Clinical Oncology, 20, 4649–4654.
   Google Scholar
• Gandhi, V. (2002) "Metabolism and mechanisms of action of bendamustine: rationales for combination therapies", Seminars in Oncology, 29 (Suppl. 13), 4–11.
   Google Scholar
• Schwänen, C., Hecker, T., Hiibinger, G., Wölfle, W., Rittgen, W., Bergmann, L., et al. (2002) "In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia", Leukemia, 16, 2096–2105.
   Google Scholar
• Chow, K.U., Boehrer, S., Geduldig, K., Krapohl, A., Hoelzer, D., Mitrou, P.S., et al. (2001) "In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine", Haematologica, 86, 485–493.
   Google Scholar
• Schöffski, P., Hagedorn, T., Grunwald, V., Paul, H., Merkle, K., Kowalski, R., et al. (2000) "Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours", Journal of Cancer Research and Clinical Oncology, 126, 41 — 47. [9]
   Google Scholar
• Schi5ffski, P., Seeland, G., Engel, H., Grunwald, V., Paul, H., Merkle, K., etal. (2000) "Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours", Annales of Oncology, 11, 729–734.
   Google Scholar
• Vermorken, J.B., Dyck, J., Van Den Brande, J., Wilmes, P., Bosmans, J. and Merkle, K. (2002) "Phase I study of single dose bendamustine hydrochloride given once every 3 weeks to patients with solid tumors", Annals of Oncology, 13 (Suppl. 5), 23.
   Google Scholar
• Gregoire, V., Ang, K.K., Rosier, J.F., Beauduin, M., Garden, AS., Hamoir, M., et al. (2002) "A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma", Radiotherapy and Oncology, 63, 187 — 193.
   Google Scholar
• Brockmann, B., Geschke, E., Schmidt, U.M. and Ebeling, K. (1991) "Therapieergebnisse und toxische Nebenwirkungen der Kombina-tion Cytostasan, Adriamycin und Vincristin als second line-Therapie beim metastasierten Mammakarzinom", GeburtshilIC und Frauenheilkunde, 51, 383–386.
   Google Scholar
• Forstpointner, R., Hand, A., Repp, R., Hermann, S., Metzner, B., Pott, C., et al. (2002) "Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas—results of a prospective randomized study of the German Low Grade Lymphoma Study Group", Deutsche Medizinische Wochens-chrift, 127, 2253–2258.
   Google Scholar